The Relationship Between Cough Reflex Sensitivity and Exacerbation Frequency in Chronic Obstructive Pulmonary Disease

Peter S. P. Cho1 · Hannah V. Fletcher2 · Richard D. Turner3 · Irem S. Patel2 · Caroline J. Jolley1 · Surinder S. Birring1,2

Received: 23 March 2020 / Accepted: 1 June 2020 / Published online: 19 June 2020
© The Author(s) 2020

Abstract
Background Cough is predictive of exacerbations of chronic obstructive pulmonary disease (COPD). Little is known about cough reflex sensitivity during exacerbation of COPD and whether it is associated with exacerbation frequency. This pilot study aimed to investigate cough reflex sensitivity during and following recovery from exacerbation of COPD, and its association with the frequency of future exacerbations. In addition, the repeatability of cough reflex sensitivity in stable COPD was investigated.

Methods Twenty participants hospitalised with exacerbation of COPD underwent inhaled capsaicin challenge during exacerbation and after 6 weeks of recovery. The frequency of future exacerbations was monitored for 12 months. The repeatability of cough reflex sensitivity was assessed in separate participants with stable COPD, who underwent 2 capsaicin challenge tests, 6 weeks apart.

Results Cough reflex sensitivity was heightened during exacerbation of COPD. Geometric mean (SD) capsaicin concentration thresholds to elicit 5 coughs (C5) during exacerbation and after 6 weeks of recovery were 1.76 (3.73) vs. 8.09 (6.25) μmol L⁻¹, respectively (p < 0.001). The change in C5 from exacerbation to 6-week recovery was associated with the frequency of future exacerbations (ρ = −0.687, p = 0.003). C5 was highly repeatable over 6 weeks in stable COPD, and intraclass correlation coefficient was 0.85.

Conclusion Cough reflex sensitivity is heightened during exacerbation of COPD and reduces after recovery. The persistence of cough reflex hypersensitivity at recovery was associated with the frequency of future exacerbations.

Keywords Cough reflex sensitivity · Cough · Chronic obstructive pulmonary disease · Exacerbation of chronic obstructive pulmonary disease

Introduction
Chronic obstructive pulmonary disease (COPD) exacerbations are acute episodes of sustained deterioration in respiratory symptoms beyond normal daily variation [1]. Such episodes are associated with impaired quality of life [2], accelerated decline in lung function [3] and increased healthcare utilisation [4]. The identification of individuals with COPD who are more susceptible to exacerbation may lead to targeted preventative therapies. Increased cough and/or sputum volume or purulence are common symptoms of COPD exacerbations [5, 6]. Independent authors have reported that higher levels of both cough symptoms and sputum production in the stable state are associated with exacerbation frequency [2, 7, 8].

The mechanism of cough in general is complex and not fully understood [9, 10]. One potential mechanism is the activation of bronchopulmonary C fibres [9]. C fibres are relatively quiescent in health but can be activated or sensitised by inflammatory mediators [11, 12]. For example, cough reflex sensitivity to capsaicin, a potent activator of C fibres, is heightened during viral upper respiratory tract infection [13, 14]. The changes in cough reflex sensitivity during acute exacerbation of COPD have not previously been investigated.

Electronic supplementary material The online version of this article (https://doi.org/10.1007/s00408-020-00366-x) contains supplementary material, which is available to authorised users.

* Surinder S. Birring
surinder.birring@nhs.net

1 Centre for Human and Applied Physiological Sciences, School of Basic and Medical Biosciences, King’s College London, London, UK

2 Department of Respiratory Medicine, King’s College Hospital NHS Foundation Trust, London, UK

3 Department of Respiratory Medicine, Charing Cross Hospital, Imperial College Healthcare Trust, London, UK
The aim of this pilot study was, firstly, to determine if cough reflex sensitivity is heightened during exacerbation of COPD and, secondly, to investigate an association between cough reflex sensitivity and exacerbation frequency. Thirdly, we sought to determine the repeatability of cough reflex sensitivity measurements in patients with stable COPD.

Methods

This was a prospective observational study of participants hospitalised with exacerbation of COPD (winter seasons of 2017/2018) and participants with stable COPD (April to August 2017), conducted at a single site (King’s College Hospital, Denmark Hill, London, UK) in accordance with the principles of the Declaration of Helsinki. The study was granted research ethics committee approval (Health Research Authority South East Scotland Research Ethics Service, 16/SS/0189). All participants provided written informed consent.

Participants

COPD Exacerbations

An exacerbation of COPD was defined as an episode of acute deterioration of respiratory symptoms associated with physiological deterioration which required additional therapy [5]. Consecutive patients admitted to hospital with an exacerbation of COPD were recruited prospectively. Initial management was according to local guidelines, with oral corticosteroids, and a combination of antibiotics, nebulised bronchodilator, inhaled meter-dosed bronchodilators and non-invasive ventilation as appropriate. Exclusion criteria were prior exposure to capsaicin challenge test, consolidation on chest radiograph, significant cognitive impairment and any additional causes for hospitalisation.

Stable COPD (Repeatability)

To investigate repeatability, a separate group of consecutive patients with COPD and stable symptoms in the preceding 6 weeks were recruited prospectively from an outpatient specialist clinic. The diagnostic criteria were a ≥ 10 pack-year smoking history and post-bronchodilator forced expiratory volume in 1 s (FEV₁) to forced vital capacity (FVC) ratio <0.70 [15]. Exclusion criteria were previous exposure to capsaicin challenge test and a history suggestive of respiratory tract infection within the previous 6 weeks.

Protocol

All participants underwent investigations at two timepoints, six weeks apart. At timepoint 1, demographic and anthropometric data were collected, and participants underwent spirometry, inhaled capsaicin tussive challenge and 24-h cough frequency monitoring. Participant-reported subjective assessments of COPD health status, cough severity and cough-specific health status were also performed. At timepoint 2, all previous measures from timepoint 1 were repeated, and the participants also underwent body plethysmography and measurements of carbon monoxide transfer factor coefficient.

COPD Exacerbation

Twenty participants underwent investigations on the day of hospital discharge following admission for exacerbation of COPD (Tₑ), and after a 6-week recovery period (Tᵣ). Medical fitness for discharge was determined by the senior attending physician [16]. Seventeen participants were then followed up by review of National Health Service electronic patient records for a period of 12 months to measure the frequency of further COPD exacerbations. Exacerbations were defined as episodes of healthcare use for their COPD with a change in medication or hospital admission as per Hurst et al. [17]. The diagnostic criteria used met the definition of moderate and severe exacerbations of COPD, exacerbations requiring a change of medication and to seek medical assistance and exacerbations requiring hospitalisation, respectively [18]. The primary and secondary care clinicians treated patients according to local clinical guidelines. Episodes of subsequent exacerbations of COPD, separated by an exacerbation-free period of ≥ 14 days, were determined from prospective review of the combined local hospital and primary care electronic patient record system [5]. All primary care practices in the local catchment area were linked to accessible electronic local care records.

Repeatability of Tussive Challenge Testing in Stable COPD

Ten separate participants with stable COPD underwent investigations over 2 visits separated by 6 weeks: T₀ and T₆, respectively.

Any participants with either exacerbation of COPD or stable COPD, who had a respiratory tract infection, an exacerbation of COPD or a change in smoking status between the 2 visits, were excluded from data analysis.
Capsaicin Tussive Challenge Test

Cough reflex sensitivity (CRS) was assessed according to the European Respiratory Society (ERS) guidelines [19]. Capsaicin solution (Sigma-Aldrich, Missouri, USA) was delivered in incremental doubling doses (0.49–1000 µmol L\(^{-1}\)) at 1-min intervals, as 10-µL single breath inhalations, via an air-powered dosimeter (KoKo Digidoser, nSpire Health Inc, Longmont, CO, USA). To diminish the effect of anticipation, 0.9% saline solution was interspersed randomly [19]. A single characterised nebuliser (DeVilbiss Healthcare, Port Washington, NY, USA) with an output of 1.232 mL min\(^{-1}\) was employed for all participants throughout the study. In addition, a valve limited inspiratory flow to 0.5 L s\(^{-1}\) [19, 20]. The number of coughs elicited by each dose administration was counted for 15 s following each dose inhalation with the aid of an audio recorder (ICD-PX333, Sony Corporation, Tokyo, Japan) [19, 20]. The challenge test continued until \(\geq 5\) coughs were elicited by a single-dose administration. The threshold concentrations of capsaicin required to elicit 1 (C1), 2 (C2) and 5 (C5) coughs were calculated by interpolation [21].

Cough Frequency Monitoring

Cough frequency was assessed objectively over 24 h with the Leicester Cough Monitor (LCM) [22]. The LCM is a validated ambulatory system, which comprises a MP3 recorder (ICD-PX333, Sony Corporation, Tokyo, Japan), a free-field lapel microphone (LFH9173, Philips, Amsterdam, Netherlands) and a semi-automated cough detection software. Coughs were detected as characteristic sounds, whether occurring in isolation or as part of a bout of prolonged coughing [22]. Total cough count (number of coughs over 24 h), mean cough frequency (coughs h\(^{-1}\) over 24 h), awake cough counts (number of coughs over estimated time spent awake) and awake 24-h cough frequency (coughs h\(^{-1}\)) were recorded. Participants recorded and reported their time spent asleep.

Subjective Assessments

COPD-Specific Health Status

COPD health status was assessed with the COPD Assessment Test (CAT), a validated self-administered 8-item questionnaire (range 0–40; lower scores indicating better health status) [23]. The CAT has been demonstrated to be responsive to changes of health status during recovery following an exacerbation of COPD [24].

Cough Severity and Cough-Specific Health Status

Cough severity was self-reported on a visual analogue scale (VAS) (range 0–100 mm; higher scores indicating more severe cough) [19]. The cough-specific health status was assessed with the Leicester Cough Questionnaire (LCQ), a self-administered 19-item assessment for cough-specific health status previously validated in COPD (range 3–21; higher scores indicating better health status) [25].

Lung Function

Spirometry, body plethysmography and diffusing capacity of carbon monoxide (Jaeger MS-PFT Analyser Unit with Sentry Suite software version 2.19.96, Vyaire Medical, Mettawa, IL, USA) were measured as per guidelines by the ERS and the American Thoracic Society [26–28].

Statistical Analysis

The distribution of data was assessed using the D’Agostino-Pearson test. Parametric data were summarised with means (standard deviation, SD), whilst non-parametric data with medians (interquartile range, IQR). Capsaicin challenge and cough frequency data were presented as geometric mean (geometric standard deviation, SD). Parametrically and non-parametrically distributed paired data were analysed with paired t test and the Wilcoxon matched-pairs signed rank test, respectively. Fisher’s exact test and Chi-squared test were used for categorical data. Correlations between variables were assessed with Pearson product-moment correlation coefficient (\(r\)) for parametric data, and Spearman’s rank-order correlation coefficient (\(\rho\)) for non-parametric data. Repeatability was analysed with the Bland–Altman method, and with intraclass correlation coefficients (ICC) based on a single-rater, absolute agreement, two-way mixed-effects model. \(p\) values < 0.05 were considered statistically significant with the exception for the analysis of factors associated with future exacerbation frequency when a Bonferroni correction was applied, whereby \(p\) values < 0.007 were considered statistically significant. The threshold concentrations of capsaicin required to elicit 1, 2 and 5 coughs (C1, C2 and C5, respectively) were calculated by interpolation of the log dose–response curve [21]. A value of 1000 µmol L\(^{-1}\) was assigned to any interpolated values which were > 1000 µmol L\(^{-1}\) [21].

A previous study has reported a significant reduction in capsaicin-evoked cough reflex sensitivity in 14 participants following recovery from an upper respiratory tract infection [13]. A study by Dicpinigaitis reported the reproducibility of...
the capsaicin cough challenge in a sample size of 10 subjects [20]. We therefore aimed to recruit 10 participants to investi-
gate the repeatability of CRS in COPD, and 15 participants
to investigate CRS during and following an exacerbation of
COPD. All analyses were performed using Prism® version 8.1.1 (GraphPad Software, San Diego, California, USA),
except the Bland–Altman and intraclass correlation corre-
lations analyses which were performed with R version 3.6.1
(R Foundation for Statistical Computing, Vienna, Austria)
for macOS version 10.14.5.

Results

Participant Characteristics

A total of 20 participants with exacerbation of COPD were
recruited; demographics, anthropometrics and clinical char-
acteristics are summarised in Table 1. The median (IQR) duration of hospital admission was 6 (3–8) days. Two par-
ticipants required acute non-invasive ventilation; no partici-
ant required invasive mechanical ventilation or organ sup-
port. All participants were discharged from hospital to their
usual place of residence, and had completed their course of
oral corticosteroid before the second visit at 6 weeks. No partici-
tant took oral azithromycin during the course of this study. Seventeen out of 20 (90%) participants agreed to par-
ticipate in the 12-month period of observation to determine
subsequent exacerbation frequency (3 participants declined to participate). Ten separate participants with stable COPD were recruited to investigate the repeatability of cough reflex
sensitivity testing and objective cough frequency (Table 2).

Exacerbation of COPD

Cough Reflex Sensitivity

Cough reflex sensitivity was heightened during exacerbation
compared to that following recovery. The capsaicin cough thresholds were significantly lower during exacerbation
\( T_E \) than at 6 weeks after recovery \( T_R \) (Table 3). The geometric mean (SD) C5 at \( T_E \) and \( T_R \) were 1.76 (3.73) vs.
8.09 (6.25) \( \mu \text{mol} \text{ L}^{-1} \), respectively, mean difference (95% CI) 2.20 (1.01–3.14) doubling doses (\( p < 0.001 \)) (Fig. 1).
The mean difference in C2 between \( T_E \) and \( T_R \) was 1.46
(\( p = 0.001 \)) doubling doses (Table 3). There were no adverse events observed or reported by patients associated with cap-
saicin cough challenge testing during acute exacerbation of
COPD. There was no significant difference in the change in C1, C2 and C5 doubling dose from \( T_E \) to \( T_R \) between gender
(\( p = 0.392, 0.640 \) and 0.624, respectively). In addition, there
was no association between the change in C5 doubling dose
from \( T_E \) to \( T_R \), and age (\( p = 0.684 \)), FEV\(_1\) (\( p = 0.333 \)) and
history of exacerbation of COPD prior to the index exacer-
bation (\( p = 0.211 \)). There were no adverse incidents associ-
ated with capsaicin challenge tests performed during acute
exacerbations in participants with COPD.

Objective Cough Frequency

Seventeen participants with exacerbation of COPD agreed
to undergo 24-h cough monitoring. The geometric mean
(SD) total 24-h cough frequency and awake cough frequen-
cy at \( T_E \) were 16.3 (2.4) and 19.3 (2.3) coughs h\(^{-1}\),
respectively (Table 3). There was a significant reduction in
total 24-h cough frequency between \( T_E \) and \( T_R \), mean differ-
ence (95% CI) 2.22 (1.43–3.44) fold difference (\( p = 0.001 \))
(Fig. 1 and Table 3). There was no significant association
between the changes in total 24-h cough frequency and
changes in cough reflex sensitivity values from \( T_E \) to \( T_R \)
(C1: \( \rho = 0.321, \ p = 0.209; \ C2: \rho = 0.355, \ p = 0.162 \) and C5:
\( \rho = 0.436, \ p = 0.082 \)). Neither was there a significant associa-
tion between total 24-h cough counts and cough reflex sensi-
tivity (C1, C2 and C5) at \( T_E \) (\( \rho = 0.147, 0.147 \) and 0.011,
respectively, all \( p > 0.50 \)).

Subjective Measures

There was a significant reduction in median (IQR) CAT
symptom scores at \( T_R \) compared to \( T_E \): 27 (21–29) vs. 30
(26–33), respectively (\( p = 0.039 \)). There was no significant
association between CAT scores and cough reflex sensitivity
(C1, C2 and C5) at \( T_E \) (Table E1), or between the changes
in CAT scores and cough reflex sensitivity (C1, C2 and C5)
from \( T_E \) to \( T_R \) (\( p = 0.569–0.953 \)).

There was a significant reduction in cough severity at
\( T_R \) compared to \( T_E \) (mean (SD) cough severity VAS scores
74 (24) vs. 40 (28) mm, respectively (\( p = 0.001 \)); Fig. 1)
and a trend towards improvement in LCQ cough health sta-
tus between these timepoints (mean (SD) LCQ total scores
14.1 (4.1) vs. 12.1 (4.3), respectively, \( p = 0.162 \)) and
history of exacerbation of COPD prior to the index exacer-
bation (\( p = 0.528–0.956 \), and \( p = 0.333–0.953 \)) and between the changes
cough reflex sensitivity (C1, C2 and C5) from \( T_E \) to \( T_R \) (\( p = 0.569–0.953 \)).

There was a significant reduction in cough reflex sensivity
(C1, C2 and C5) and either cough severity or LCQ cough-
specific health status scores at \( T_E \) (Table E1), or between
change in cough reflex sensitivity (C1, C2 and C5) and
change in either cough severity or LCQ cough health sta-
tus from \( T_R \) to \( T_R \) (\( p = 0.549–0.814 \), and \( p = 0.528–0.956 \),
respectively).
Table 1: COPD exacerbation group: demographics and clinical characteristics of participants during exacerbation and 6 weeks following recovery

|                                | Participants with exacerbation of COPD (n = 20) | 6-week recovery | p values |
|--------------------------------|-------------------------------------------------|-----------------|----------|
|                                | Admission                                       |                 |          |
| Age (years)                    | 67.5 (6.3)                                     | N/A             |          |
| Gender (female)                | 12 (60)                                        | N/A             |          |
| BMI (kg m⁻²)                   | 27.4 (7.3)                                     | N/A             |          |
| Smoking status                 |                                                 |                 |          |
| Ex                             | 15 (75)                                        | 15 (75)         | > 0.999<|
| Current                        | 5 (25)                                         | 5 (25)          |          |
| MRC dyspnoea scale (stable state) | N/A                  | 4 (3–5)        |          |
| CAT                            | 30 (26–33)                                     | 27 (21–29)      | 0.039<   |
| Spirometry                     |                                                 |                 |          |
| FEV₁, % predicted             | 34.0 (10.1)                                    | 43.5 (15.0)     | 0.004<   |
| FVC % predicted               | 65.4 (15.5)                                    | 83.8 (15.0)     | < 0.001< |
| Body plethysmography<         | N/A                                             |                 |          |
| TLC % predicted                |                                                 | 122.9 (108.0–130.4) |          |
| RV % predicted                 |                                                 | 155.5 (39.1)    |          |
| Diffusion capacity             |                                                 |                 |          |
| TLC<CO % predicted            |                                                 | 52.3 (16.7)     |          |
| K<CO % predicted               |                                                 | 59.9 (23.9)     |          |
| GOLD stage*                    |                                                 |                 |          |
| GOLD 1                         | 0 (0)                                          |                 |          |
| GOLD 2                         | 5 (25)                                         |                 |          |
| GOLD 3                         | 11 (55)                                        |                 |          |
| GOLD 4                         | 3 (15)                                         |                 |          |
| Co-morbidities                 |                                                 |                 |          |
| Ischaemic heart disease        | 5 (25)                                         |                 |          |
| Cerebrovascular disease        | 2 (10)                                         |                 |          |
| Hypertension                   | 11 (55)                                        |                 |          |
| Diabetes mellitus              | 4 (20)                                         |                 |          |
| Index exacerbation             |                                                 |                 |          |
| Duration of exacerbation symptom pre-admission | 3 (2–9) |                 |          |
| Systemic steroids use pre-admission | 9 (45) |                 |          |
| Antibiotics use pre-admission | 9 (45)                                         |                 |          |
| Admission vital signs          |                                                 |                 |          |
| Temperature (°C)               | 37.0 (0.5)                                     |                 |          |
| Heart rate (min⁻¹)             | 96 (13)                                        |                 |          |
| Respiratory rate (min⁻¹)       | 21 (3)                                         |                 |          |
| SpO₂ (%)                       | 94 (89–95)                                     |                 |          |
| Routine laboratory test on admission |                                                 |                 |          |
| Leucocytes (× 10⁹ L⁻¹)         | 10.89 (3.96)                                   |                 |          |
| Neutrophils (× 10⁹ L⁻¹)        | 8.06 (3.65)                                    |                 |          |
| Eosinophils (× 10⁹ L⁻¹)        | 0.24 (0.21)                                    |                 |          |
| Haemoglobin (g L⁻¹)            | 140 (15)                                       |                 |          |
| C-reactive protein (mg L⁻¹)    | 40 (69)                                        |                 |          |
| Duration of admission (days)   | 6 (3–8)                                        | N/A             |          |

Data presented as mean (SD), median (IQR) or absolute values (percentage)

BMI body mass index, MRC Medical Research Council, CAT COPD Assessment Tool, FEV₁, forced expiratory volume in 1 s, FVC = forced vital capacity, TLC total lung capacity, RV residual volume, TLCO carbon monoxide transfer factor, K<CO carbon monoxide transfer coefficient, GOLD Global Initiative for Chronic Obstructive Pulmonary Disease, SpO₂ transcutaneous oxygen saturation

<\n = 19
\n = 13
\n = 16
\n Fisher’s exact test
\n Paired t test
Association Between Cough Reflex Sensitivity and Future Exacerbation Frequency

Subsequent exacerbations of COPD occurred in 15 of the 17 individuals who were followed up for 12 months following the initial hospitalisation. The mean (SD) number of further COPD exacerbations per participant during follow-up was 2.5 (2.0) episodes. There were a total of 42 exacerbation episodes, of which 30 led to utilisation of primary care services, 12 to presentation to the emergency department, and 9 to hospital admission. The median (IQR) time to the next exacerbation following recruitment at $T_E$ was 135 (78–238) days.

There was a significant association between the change in C5 from $T_E$ to $T_R$ and the rate of acute exacerbation of COPD in the following 12 months ($\rho = -0.687$, $p = 0.003$) (Table 4 and Fig. 2). In addition, there was no significant association between the rate of exacerbation of COPD in the following 12 months and the changes from $T_E$ to $T_R$ in either objective cough frequency, CAT scores ($p = 0.116$), cough severity VAS ($p = 0.596$), LCQ or FEV$_1$% predicted (Table 4 and Fig. 3). Neither at time $T_E$ or $T_R$ was there an association between the rate of exacerbation of COPD in the following 12 months and CRS, objective cough frequency, CAT scores, cough severity VAS, LCQ or FEV$_1$% predicted (all $p > 0.06$).

Repeatability of Cough Reflex Sensitivity and Objective Cough Frequency in Stable COPD

No participant was excluded from the study of CRS repeatability. Intraclass correlation coefficients to determine repeatability of the cough reflex sensitivity measures log(C1), log(C2) and log(C5) were 0.37, 0.54 and 0.85, respectively, in participants with stable COPD (Table 5). The mean differences (95% CI) in C1, C2 and C5 over 6 weeks were 0.34 (−0.13–2.40), 0.31 (−0.11–2.16) and 0.21 (−0.40–1.79) doubling doses, respectively (Fig. 4). C5 was the most repeatable capsaicin challenge test threshold and was therefore used for the main analysis.

For objective cough frequency, the ICC coefficients for repeatability of log(total 24-h cough count), log(total cough frequency), log(awake cough count) and log(awake cough frequency) over 6 weeks were 0.86, 0.85, 0.70 and 0.84, respectively (Table 5). The mean differences (95% CI) in C1, C2 and C5 over 6 weeks were 0.34 (−0.13–2.40), 0.31 (−0.11–2.16) and 0.21 (−0.40–1.79) doubling doses, respectively (Fig. 4). C5 was the most repeatable capsaicin challenge test threshold and was therefore used for the main analysis.

Discussion

We investigated the sensitivity of the cough reflex during exacerbations of COPD and its relationship with the frequency of future exacerbations. Cough reflex sensitivity
CRS was heightened during exacerbations of COPD. The magnitude of change in cough reflex sensitivity 6 weeks after hospitalisation for exacerbation was associated with the frequency of future exacerbations. There was no association between subjective cough severity, objective cough frequency or FEV₁ and the frequency of exacerbations. In stable COPD patients, C5 was the most repeatable measure of CRS.

To the best of our knowledge, our study is the first to investigate CRS during exacerbations of COPD. CRS to capsaicin was heightened during exacerbation. Viral upper respiratory tract infections are commonly associated with exacerbations of COPD [29]. There are studies which have investigated CRS in healthy subjects with acute cough associated with upper respiratory tract infection [13, 14]. O’Connell et al. demonstrated that CRS was heightened during exacerbation of COPD. Viral upper respiratory tract infections are commonly associated with exacerbations of COPD [29].
during upper respiratory tract infection, and reduced following 4 weeks of recovery in healthy participants with non-productive cough [13]. Dicpinigaitis et al. also reported that CRS to capsaicin was heightened during upper respiratory tract infection, and reduced following 4 weeks of recovery [14]. Capsaicin is a selective agonist of transient receptor potential vanilloid 1 ion channel receptors (TRPV1), which are expressed on C-fibre sensory nerves [30]. Bronchopulmonary C fibres are relatively quiescent in health and can be sensitised or activated by inflammatory mediators [11]. Exposure to ozone [12], lactic acid [12], cationic proteins [31] and prostaglandin-E2 [11] are known to enhance pulmonary C-fibre responses to mechanical and chemical stimuli in a reversible fashion. Airway inflammation in exacerbation of COPD could therefore lead to sensitisation or activation of C fibres.

A key finding from our study was that the magnitude of change in CRS following an exacerbation was associated with prospective frequency of exacerbations. The frequency of exacerbation in our study was comparable to those in previous studies [2, 17]. Further exacerbations were more frequent in individuals demonstrating a lower reduction in cough reflex sensitivity at six weeks after the index episode. Previous studies have investigated the predictive factors for exacerbations of COPD, including exacerbation frequency in the preceding 12 months, disease severity, gastro-oesophageal reflux and health status [17, 32]. A failure of CRS to change during recovery from exacerbation has not been previously studied as a potential marker of future exacerbation risk. Terada et al. conducted the only study of CRS and its association with exacerbations, and investigated CRS in patients with stable COPD [33]. In contrast to our findings, Terada et al. did not find an association between CRS and exacerbation of COPD defined by a change of medication [33]. There are several key differences between the studies that may explain the contrasting findings. Terada et al. assessed a single measure of CRS during a stable phase and did not assess it longitudinally for the persistence of CRS following exacerbation of COPD [33]. Terada et al. did however report a weak correlation with frequency of exacerbations of COPD when defined on the basis of a change in therapy for exacerbation of COPD [33].

A strength of the current study is that measurement of the change in CRS within the same individual at two time points controls for much of the large variation in cough reflex sensitivity that we have confirmed to exist between subjects in the stable state in COPD. This large inter-individual variation in CRS might explain the apparent lack of association between absolute values of C5 and COPD exacerbation frequency.

The mechanism by which a persistently heightened cough reflex sensitivity may predispose to future exacerbations is not clear. An associated persistence of airway inflammation following an exacerbation may be important but this has seldom been studied. Airway inflammation in patients with stable COPD however has been reported to predispose to exacerbations. Bhowmik et al. demonstrated that raised levels of cytokines, IL-6 and 8, in sputum were associated with frequent exacerbations [34]. Gompertz et al. reported reduced levels of sputum protease inhibitors in those with

| Table 4 | Relationship between cough and 12-month prospective frequency of exacerbation of chronic obstructive pulmonary disease |
|-----------------------------------------------|
| Future 12-month exacerbation count |
| Correlation coefficients | p values |
|-----------------------------------------------|
| Admission vs. 6-week recovery |
| Cough reflex sensitivity (C5)* | -0.687 | 0.003 |
| Total cough count (coughs)* | -0.064 | 0.827 |
| Awake cough count (coughs)* | 0.033 | 0.912 |
| LCQ | 0.244* | 0.345 |
| FEV1% predicted | -0.075b | 0.783 |

All correlation coefficients are Spearman’s rank-order correlations unless stated otherwise. Bonferroni correction was applied and p values < 0.007 were considered significant. Significant p values are given in bold. C5 capsaicin concentration required to elicit 5 coughs, VAS visual analogue scale, LCQ Leicester Cough Questionnaire, CAT COPD Assessment Test, FEV1 forced expiratory volume in 1 s.

*aDoubling dose change

*bFold difference
cPearson product-moment correlation

Fig. 2 The relationship between the change in cough reflex sensitivity following exacerbation of chronic obstructive pulmonary disease and future exacerbations.
frequent COPD exacerbations [35]. Another possible mechanism for persistent cough reflex sensitivity, and predisposition for future exacerbation and symptoms, is changes in central neural pathways and cognitive influences, such as those that have been reported in inflammatory airway diseases such as asthma using functional neuroimaging [36].

The assessment of CRS may be a tool to identify patients at high risk of future exacerbations. The existing cough challenge methodology is not practical for routine clinical use and simpler protocols would need to be developed. The capsaicin challenge test was however well tolerated by severe COPD patients suffering from acute exacerbation study. This is the first study to assess cough reflex sensitivity during an exacerbation and may facilitate future research investigating the mechanisms involved in exacerbation of COPD. It is not possible to elucidate the mechanism between the magnitude of change in CRS following exacerbation and the frequency of future exacerbations from our study. A better understanding of this mechanism may lead to targeted therapy for the prevention of exacerbations.

Table 5: Repeatability of capsaicin challenge test, objective cough frequency and cough severity over 6 weeks in participants with stable chronic obstructive pulmonary disease

|                          | Week 1 | Week 6 | ICC  |
|--------------------------|--------|--------|------|
| Cough reflex sensitivity  |        |        |      |
| C1 (μmol L⁻¹)            | 0.93 (2.89) | 2.04 (3.90) | 0.37 |
| C2 (μmol L⁻¹)            | 1.50 (3.14) | 3.05 (4.13) | 0.54 |
| C5 (μmol L⁻¹)            | 6.29 (8.44) | 10.20 (7.45) | 0.85 |
| 24-h cough monitoring*   |        |        |      |
| Total cough count (coughs) | 124.7 (4.1) | 165.0 (2.6) | 0.86 |
| Total cough frequency (coughs h⁻¹) | 5.1 (4.2) | 6.9 (2.5) | 0.85 |
| Awake cough count (coughs) | 101.5 (3.9) | 134.0 (2.4) | 0.70 |
| Awake cough frequency (coughs h⁻¹) | 6.5 (3.9) | 8.4 (2.4) | 0.84 |
| Cough severity VAS (mm)  | 37 (23) | 45 (30) | 0.56 |

Data presented as geometric mean (SD) or mean (SD).
ICC intraclass correlation coefficient, C1 capsaicin concentration required to elicit 1 cough, C2 capsaicin concentration required to elicit 2 coughs, C5 capsaicin concentrations required to elicit 5 coughs, VAS visual analogue scale.

Fig. 3: The relationship between COPD exacerbation frequency and change between exacerbation and 6-week recovery visit in cough severity visual analogue scale score, objective cough frequency and forced expiratory volume in 1 s. a Cough severity visual analogue scale. b Total (24-h) cough frequency. c Forced expiratory volume in 1 s.

Fig. 4: Repeatability of capsaicin cough challenge test threshold to elicit 5 coughs (C5) during capsaicin challenge test in stable chronic obstructive pulmonary disease. a C5 (6 weeks apart) in stable COPD. b Bland–Altman plot of C5 (6 weeks apart) in stable COPD.
Previous studies have investigated whether other measures of cough predict COPD exacerbation frequency, with conflicting findings. Burgel et al. and Seemungal et al. reported that the presence of self-reported cough is associated with exacerbation frequency in stable COPD [2, 7]. In contrast, Hurst et al. [17], in common with this current study, did not find an association between self-reported cough and numbers of exacerbation of COPD. Neither did we observe an association between objective cough counts and exacerbation frequency. Objective CRS, subjective symptom scales and objective cough counts assess very different dimensions of cough, and a poor association between them is well reported [37]. It is likely that CRS reflects the interaction between airway inflammation and sensory nerves.

There are limitations to our study. We studied a relatively small sample size and were therefore unable to assess the predictors of exacerbations of COPD with multivariate regression analysis. Our patients had severe COPD and therefore our findings should be interpreted with caution for those with mild disease. We were also unable to assess the effects of factors such as smoking status that may influence CRS due to the small sample size. To standardise the timing of the cough challenge test during the hospital admission, patients were assessed on the first day that they were deemed fit for a challenge test by the clinical and research teams. It is possible that the variability of the timing of the cough challenge test between the patients may have impacted the cough reflex sensitivity assessment. The assessment of CRS in the recovery phase may have been too soon after the exacerbation. We did, however, demonstrate that CRS is highly repeatable over 6 weeks in stable COPD with no order effect. Furthermore, the CRS values following recovery from exacerbation in our study were similar to those reported previously in stable COPD by Sumner et al. [38]. FEV$_1$% predicted during exacerbation, following recovery and the change between 2 occasions were not associated with the frequency of future exacerbations despite previous reports of an association between severity of COPD according to FEV$_1$% predicted and exacerbation frequency [17, 39]. This may be due to the small sample size and the relatively limited range of disease severity in our study. Patients with more severe disease were more likely to have exacerbations, and therefore be included in our study. The subjective cough measures were not associated with CRS, which may be due to the small sample size in our study. This is not unexpected as health status and CRS assess very different dimensions of cough, and is consistent with previous reports [37, 40]. We did not find an association between cough reflex sensitivity and objective cough frequency, and this is consistent with a previous study reporting a poor association [38].

The technology for measuring cough frequency in the current study has not yet been widely used in COPD, but is well established in chronic cough in other contexts [40]. Validity for our approach though is suggested by the similar magnitude and range of cough frequencies we report in stable COPD compared to those of a study by Sumner et al. using an alternative method to determine cough frequency [38]. Whilst there was a slight excess of female participants in our cohort, there was no significant difference in C5 between gender. A slight excess of female participants is consistent with other studies of patients hospitalised for exacerbation of COPD [16, 41]. Whilst C5 generally appeared a repeatable measure of cough

![Fig. 5 Bland–Altman plot assessing the repeatability of threshold capsaicin concentrations during capsaicin challenge test, objective cough frequency and cough severity visual analogue scale over 6 weeks in participants with stable chronic obstructive pulmonary disease. a Total cough frequency. b Awake cough count. c Awake cough frequency. d Cough severity visual analogue scale](image-url)
reflex sensitivity, this observation was not universal; some participants with stable COPD demonstrated marked differences in C5 between the two timepoints. This may therefore impact the utility of the C5 test in future studies. We did not investigate the cause of COPD exacerbation or markers of inflammation in sputum and serum, and these should be assessed in future studies. We only assessed CRS with inhaled capsaicin. It is possible that COPD patients may respond differently to other tussive agents, and produce different results [42, 43].

In conclusion, cough reflex sensitivity is heightened during acute exacerbation of COPD and is associated with the frequency of future exacerbations. Further studies are needed to replicate our findings in a larger study, and to investigate the mechanisms for persistent cough reflex hypersensitivity as this may lead to targeted therapy for the prevention of COPD exacerbations.

Acknowledgements The authors thank all the patients for their participation in the study. We would like to thank the integrated respiratory team, Chest Unit and the staff of the COPD clinic at King’s College Hospital for their assistance in characterising the patients.

Author Contributions Conception and design: SB, CJJ, PC, RT, HF and IP; Participants screening: PC; Study recruitment: PC; Data analysis: PC; Interpretation of data: PC, SB and RT; Drafting manuscript: PC, SB, RT, HF, CJJ and IP; Revised manuscript: SB, PC, RT, HF, CJJ and IP.

Funding PC has received grant funding from Merck. SB has received grant funding from Merck and personal fees for consulting from Merck, Bayer, GSK, Shionogi, Bellus, NeRRe.

Compliance with Ethical Standards

Conflict of interest HF, RT, IP and CJJ declare no conflicts of interest.

Ethical Approval Health Research Authority South East Scotland Research Ethics Service, 16/SS/0189.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. The National Institute for Health and Care Excellence (NICE) (2018) Chronic obstructive obstructive pulmonary disease in over 16s: diagnosis and management. London

2. Seemungal T, Donaldson G, Paul E et al (1998) Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 157:1418–1422

3. Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha JA (2002) Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 57:847–852

4. Sullivan SD, Ramsey SD, Lee TA (2009) The economic burden of COPD. Chest 117:55–9S

5. Seemungal TAR, Donaldson GC, Bhowmik A et al (2000) Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 161:1608–1613

6. Crooks MG, Hayman Y, Innes A et al (2016) Objective measurement of cough frequency during COPD exacerbation convalescence. Lung 194:117–120

7. Burgel PR, Nesme-Meyer P, Chanez P et al (2009) Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest 135:975–982

8. Foreman MG, DeMeo DL, Hersh CP et al (2007) Clinical determinants of exacerbations in severe, early-onset COPD. Eur Respir J 30:1124–1130

9. Mazzone SB, Farrell MJ (2019) Heterogeneity of cough neurobiology: clinical implications. Pulm Pharmacol Ther 55:62–66

10. Chung KF, Mcgarvey L, Mazzone SS (2013) Chronic cough as a neuropathic disorder. Lancet Respir Med 1:414–422

11. Ho CY, Gu Q, Hong JL, Lee LY (2000) Prostaglandin E2 enhances chemical and mechanical sensitivities of pulmonary C fibers the rat. Am J Respir Crit Care Med 162:528–533

12. Ho C, Lee L (1998) Ozone enhances excitabilities of pulmonary C fibers to chemical and mechanical stimuli in anesthetized rats. J Appl Physiol 85:1509–1515

13. O’Connell F, Thomas VE, Studham JM et al (1996) Capsaicin cough sensitivity increases during upper respiratory infection. Respir Med 90:279–286

14. Dicpinigaitis PV, Tibb AS, Ramsey DL et al (2014) Stability of cough reflex sensitivity during viral upper respiratory tract infection (common cold). Pulm Pharmacol Ther 28:154–157

15. National Institute for Health and Care Excellence (2010) CG101 Chronic obstructive pulmonary disease (update): full guideline. London

16. Suh E-S, Mandal S, Harding R et al (2015) Neural respiratory drive predicts clinical deterioration and safe discharge in exacerbations of COPD. Thorax 70:1123–1130

17. Hurst JR, Vestbo J, Anzueto A et al (2010) Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 363:1128–1138

18. Rodriguez-Roisin R (2000) Toward a consensus definition for COPD exacerbations. Chest 117:398S–401S

19. Morice AH, Fontana GA, Belvisi MG et al (2007) ERS guidelines on the assessment of cough. Eur Respir J 29:1256–1276

20. Dicpinigaitis PV (2003) Short- and long-term reproducibility of capsaicin cough challenge testing. Pulm Pharmacol Ther 16:61–65

21. Prudon B, Birring SS, Vara DD et al (2005) Cough and glottic-stop reflex sensitivity in health and disease. Chest 23:550–557

22. Birring SS, Fleming T, Matos S et al (2008) The leicester cough monitor: preliminary validation of an automated cough detection system in chronic cough. Eur Respir J 31:1013–1018

23. Jones PW, Harding G, Berry P et al (2009) Development and first validation of the COPD assessment test. Eur Respir J 34:648–654

24. Jones PW, Harding G, Wiklund I et al (2012) Tests of the responsiveness of the COPD assessment test following acute exacerbation and pulmonary rehabilitation. Chest 142:134–140
25. Berkhof FF, Boom LN, ten Hertog NE et al (2012) The validity and precision of the leicester cough questionnaire in COPD patients with chronic cough. Health Qual Life Outcomes 10:4
26. Miller MR, Hankinson J, Brusasco V et al (2005) Standardisation of spirometry. Eur Respir J 26:319–338
27. Graham BL, Brusasco V, Burgos F et al (2017) 2017 ERS/ATS standards for single-breath carbon monoxide uptake in the lung. Eur Respir J 49:1600016
28. Wanger J, Clausen JL, Coates A et al (2005) Standardisation of the measurement of lung volumes. Eur Respir J 26:511–522
29. Papi A, Luppi F, Franco F, Fabbri LM (2006) Pathophysiology of exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc 3:245–251
30. Laloo UG, Fox AJ, Belvisi MG et al (1995) Capsazepine inhibits cough induced by capsaicin and citric acid but not by hypertonic saline in guinea pigs. J Appl Physiol 79:1082–1087
31. Gu Q, Lee L (2001) Hypersensitivity of pulmonary C fibre afferents induced by cationic proteins in the rat. J Physiol 537:887–897
32. Quint JK, Donaldson GC, Hurst JR et al (2011) Predictive accuracy of patient-reported exacerbation frequency in COPD. Eur Respir J 37:501–507
33. Terada K, Muro S, Ohara T et al (2009) Cough-reflex sensitivity to inhaled capsaicin in COPD associated with increased exacerbation frequency. Respirology 14:1151–1155
34. Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA (2000) Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 55:114–120
35. Gompertz S, Bayley DL, Hill SL, Stockley RA (2001) Relationship between airway inflammation and the frequency of exacerbations in patients with smoking related COPD. Thorax 56:36–41
36. Rosenkranz MA, Busse WW, Johnstone T et al (2005) Neural circuitry underlying the interaction between emotion and asthma symptom exacerbation. Proc Natl Acad Sci USA 102:13319–13324
37. Faruqi S, Thompson R, Wright C et al (2011) Quantifying chronic cough: Objective versus subjective measurements. Respirology 16:314–320
38. Sumner H, Woodcock A, Kolsum U et al (2013) Predictors of objective cough frequency in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 187:943–949
39. Müllerová H, Shukla A, Hawkins A, Quint J (2014) Risk factors for acute exacerbations of COPD in a primary care population: a retrospective observational cohort study. BMJ Open 4:e006171
40. Birring SS, Spinou A (2015) How best to measure cough clinically. Curr Opin Pharmacol 22:37–40
41. Murphy PB, Kumar A, Reilly C et al (2011) Neural respiratory drive as a physiological biomarker to monitor change during acute exacerbations of COPD. Thorax 66:602–608
42. Long L, Yao H, Tian J et al (2019) Heterogeneity of cough hypersensitivity mediated by TRPV1 and TRPA1 in patients with chronic refractory cough. Respir Res 20:1–9
43. Belvisi MG, Birrell MA, Khalid S et al (2016) Neurophenotypes in airway diseases: Insights from translational cough studies. Am J Respir Crit Care Med 193:1364–1372

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.